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We appreciate the comments on our study “Basal C-peptide 
level as a surrogate marker of subclinical atherosclerosis in 
type 2 diabetes patients,” which was published in Diabetes & 
Metabolism Journal 2011;35:41-49 [1]. 
  Many studies have reported that high levels of HbA1c are 
strongly associated with increased risks of cardiovascular dis-
ease and microvascular complications [2]. However, recent 
studies have reported that while the use of intensive therapy to 
target glycated hemoglobin levels below 6% reduces 5-year 
nonfatal myocardial infarctions, it increases 5-year mortality 
[3]. Other studies have reported that high density lipoprotein 
cholesterol, but probably not HbA1c, influences cardiovascu-
lar outcomes [4]. It is still unknown, however, whether HbA1c 
levels are associated with macrovascular complications such as 
stroke, atherosclerosis, cardiovascular disease, and peripheral 
arterial disease. 
  In our study [1], the 10-year risk of coronary heart disease 
(CHD) was calculated according to the United Kingdom Pro-
spective Diabetes Study (UKPDS) risk engine for each patient 
based on smoking status, total serum cholesterol, age, serum 
low density lipoprotein cholesterol, and systolic blood pressure. 
However, the 10-year CHD risk engine does not take levels of 
glucose or HbA1c into account. Therefore, in the present study, 
we show that basal C-peptide is not associated with UKPDS 
risk engine-related factors and does not independently influ-
ence 10-year CHD risk. However, intima media thickness 
(IMT) can be directly assessed based on arterial vessel wall 
changes and smooth muscle cell (SMC) proliferation. Insulin 
resistance and C-peptide are associated with SMC prolifera-
tion. Therefore, C-peptide is thought to be an independent 
factor predicting IMT. In the Atherosclerosis Risk in the Com-
munities (ARIC) study [5], higher levels of endogenous insu-
lin were significantly associated with increased thickness of 
the carotid artery wall. Reducing the levels of C-peptide and 
insulin resistance in type 2 diabetic patients, who are especial-
ly likely to exhibit many components of metabolic syndrome, 
may be improved in the outcomes of cases with cardiovascular 
complications. 
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